A short course of immunotherapy given before surgery eliminated detectable colon cancer in a majority of patients whose ...

Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.

Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...

ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Abstracts Presented at ASCO 2026 In June 2026, Atossa Therapeutics, Inc. (NASDAQ: ATOS) announced that two abstracts were presented at the 2026 ...

Q3 2026 FDA oncology verdicts loom for ADCs and targeted drugs in breast, melanoma, gastric, blood, and lung cancers. The third quarter of 2026 brings a fresh slate of high-stakes FDA decisions across ...

Among 98 patients with stage II to III disease, the 5-year event-free survival rate was 99%, the recurrence-free interval was ...

Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven ...

On track for enrollment of 80 participants by Q1 2027Trial is supported by Phase 2 results showing significant improvement in overall survival in ...

Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven ...

The emergence of immunotherapy for esophageal cancer provided a glimmer of hope to patients and clinicians affected by the historically poor-prognosis disease. The glimmer has not only persisted but ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...

Liver transplantation remains one of the most powerful curative options for hepatocellular carcinoma (HCC) because it removes both the tumor and the diseased liver.